


Appendix A

Claim Amendments

1. (Currently amended) A compound of formula 1,



in which

R1 is 1-4C-alkyl,

R2 is hydroxyl, 1-4C-alkoxy, 3-7C-cycloalkoxy, 3-7C-cycloalkylmethoxy, or 1-4C-alkoxy which is completely or predominantly substituted by fluorine,

R3 is hydroxyl, 1-4C-alkoxy, 3-7C-cycloalkoxy, 3-7C-cycloalkylmethoxy, or 1-4C-alkoxy which is completely or predominantly substituted by fluorine,

or in which

R2 and R3 together are a 1-2C-alkylenedioxy group,

R4 is hydrogen, halogen, nitro, 1-4C-alkyl, trifluoromethyl or 1-4C-alkoxy,

R5 is hydrogen or 1-8C-alkyl,

R6 is hydrogen, 1-8C-alkylcarbonyl, 3-7C-cycloalkylcarbonyl, 3-7C-cycloalkylmethylcarbonyl, Arylcarbonyl, or Aryl-1-4C-alkylcarbonyl ~~bedeutet~~,

Aryl is phenyl or phenyl substituted by R7 and/or R8,

R7 is halogen, nitro, 1-4C-alkyl or 1-4C-alkoxy,

R8 is halogen, nitro, 1-4C-alkyl or 1-4C-alkoxy,

n is 1 or 2,

or a hydrate, solvate, salt, hydrate of a salt or solvate of a salt thereof, or an N-oxide thereof or a salt of the N-oxide.

2. (Previously presented) A compound of formula 1 as claimed in claim 1, in which

R1 is 1-4C-alkyl,

R2 is 1-4C-alkoxy, 3-6C-cycloalkoxy, 3-6C-cycloalkylmethoxy,  
or 1-4C-alkoxy which is completely or predominantly  
substituted by fluorine,

R3 is 1-4C-alkoxy, 3-6C-cycloalkoxy, 3-6C-cycloalkylmethoxy,  
or 1-4C-alkoxy which is completely or predominantly  
substituted by fluorine,

R4 is hydrogen, halogen, nitro, 1-4C-alkyl, trifluoromethyl or  
1-4C-alkoxy,

R5 is hydrogen or 1-4C-alkyl,

R6 is hydrogen, 1-4C-alkylcarbonyl, 3-7C-cycloalkylcarbonyl,  
3-7C-cycloalkylmethylcarbonyl, Arylcarbonyl or Aryl-1-2C-  
alkylcarbonyl,

Aryl is phenyl or phenyl substituted by R7 and/or R8,

R7 is halogen, nitro, 1-4C-alkyl or 1-4C-alkoxy,

R8 is halogen, nitro, 1-4C-alkyl or 1-4C-alkoxy,

n is 1 or 2,

or a hydrate, solvate, salt, hydrate of a salt or solvate of a  
salt thereof, or an N-oxide thereof or a salt of the N-oxide.

3. (Previously presented) A compound of formula 1 as claimed  
in claim 1, in which

R1 is methyl,

R2 is 1-4C-alkoxy,

R3 is 1-4C-alkoxy,

R4 is hydrogen,

R5 is 1-4C-alkyl,

R6 is hydrogen, 1-4C-alkylcarbonyl, Arylcarbonyl or Aryl-1-2C-alkylcarbonyl,

Aryl is phenyl or phenyl substituted by R7 and/or R8,

R7 is nitro, 1-2C-alkyl or 1-2C-alkoxy,

R8 is 1-2C-alkoxy,

n is 1 or 2,

or a hydrate, solvate, salt, hydrate of a salt or solvate of a salt thereof, or an N-oxide thereof or a salt of the N-oxide.

4. (Previously presented) A compound of formula 1 as claimed in claim 1, in which

R1 is methyl,

R2 is methoxy or ethoxy,

R3 is methoxy,

R4 is hydrogen,

R5 is isopropyl,

and in which either

R6 is hydrogen, phenylcarbonyl, benzylcarbonyl, 4-nitrophenylcarbonyl, 3-4-dimethoxyphenylcarbonyl, 3-5-dimethoxyphenylcarbonyl or acetyl and

n is 1,

or

R6 is phenylcarbonyl, benzylcarbonyl or 3,4-dimethoxy-benzylcarbonyl and

n is 2,

or a hydrate, solvate, salt, hydrate of a salt or solvate of a salt thereof, or an N-oxide thereof or a salt of the N-oxide.

5. (Previously presented) A compound of formula 1 as claimed in claim 1, in which

R1 is methyl,

R2 is methoxy or ethoxy,

R3 is methoxy,

R4 is hydrogen,

R5 is isopropyl,

and in which either

R6 is hydrogen, benzylcarbonyl, 4-nitrophenylcarbonyl, 3,4-dimethoxyphenylcarbonyl, 3,5-dimethoxyphenylcarbonyl or acetyl and

n is 1,

or

R6 is phenylcarbonyl, benzylcarbonyl or 3,4-dimethoxy-benzylcarbonyl and

n is 2,

or a hydrate, solvate, salt, hydrate of a salt or solvate of a salt thereof, or an N-oxide thereof or a salt of the N-oxide.

6. (Previously presented) A compound of formula 1 as claimed in claim 1 selected from the group consisting of

Phenyl-acetic acid (S)-2-({1-[4-((4aR,10bS)-9-ethoxy-8-methoxy-2-methyl-1,2,3,4,4a,10b-hexahydro-benzo[c][1,6]naphthyridin-6-yl)-phenyl]-methanoyl}-isopropyl-amino)-propyl ester,

Benzoic acid (S)-2-({1-[4-((4aR,10bS)-9-ethoxy-8-methoxy-2-methyl-1,2,3,4,4a,10b-hexahydro-benzo[c][1,6]naphthyridin-6-yl)-phenyl]-methanoyl}-isopropyl-amino)-propyl ester,

3,4-Dimethoxy-benzoic acid (S)-2-({1-[4-((4aR,10bS)-9-ethoxy-8-methoxy-2-methyl-1,2,3,4,4a,10b-hexahydro-benzo[c][1,6]-naphthyridin-6-yl)-phenyl]-methanoyl}-isopropyl-amino)-propyl ester,

3,5-Dimethoxy-benzoic acid (S)-2-({1-[4-((4aR,10bS)-9-ethoxy-8-methoxy-2-methyl-1,2,3,4,4a,10b-hexahydro-benzo[c][1,6]-naphthyridin-6-yl)-phenyl]-methanoyl}-isopropyl-amino)-propyl ester,

Acetic acid (S)-2-({1-[4-((4aR,10bS)-9-ethoxy-8-methoxy-2-methyl-1,2,3,4,4a,10b-hexahydro-benzo[c][1,6]naphthyridin-6-yl)-phenyl]-methanoyl}-isopropyl-amino)-propyl ester,

Benzoic acid 3-({1-[4-((4aR,10bS)-9-ethoxy-8-methoxy-2-methyl-1,2,3,4,4a,10b-hexahydro-benzo[c][1,6]naphthyridin-6-yl)-phenyl]-methanoyl}-isopropyl-amino)-butyl ester,

Phenyl-acetic acid 3-({1-[4-((4aR,10bS)-9-ethoxy-8-methoxy-2-methyl-1,2,3,4,4a,10b-hexahydro-benzo[c][1,6]naphthyridin-6-yl)-phenyl]-methanoyl}-isopropyl-amino)-butyl ester,

(3,4-Dimethoxy-phenyl)-acetic acid 3-({1-[4-((4aR,10bS)-9-ethoxy-8-methoxy-2-methyl-1,2,3,4,4a,10b-hexahydro-benzo[c][1,6]naphthyridin-6-yl)-phenyl]-methanoyl}-isopropyl-amino)-butyl ester,

4-Nitro-benzoic acid (S)-2-({1-[4-((4aR,10bS)-9-ethoxy-8-methoxy-2-methyl-1,2,3,4,4a,10b-hexahydro-benzo[c][1,6]naphthyridin-6-yl)-phenyl]-methanoyl}-isopropyl-amino)-propyl ester,

4-Nitro-benzoic acid (R)-2-({1-[4-((4aR,10bS)-9-ethoxy-8-methoxy-2-methyl-1,2,3,4,4a,10b-hexahydro-benzo[c][1,6]naphthyridin-6-yl)-phenyl]-methanoyl}-isopropyl-amino)-propyl ester,

4-((4aR,10bS)-9-Ethoxy-8-methoxy-2-methyl-1,2,3,4,4a,10b-hexahydro-benzo[c][1,6]naphthyridin-6-yl)-N-((S)-2-hydroxy-1-methyl-ethyl-N-isopropyl-benzamide,


4-((4aR,10bS)-9-Ethoxy-8-methoxy-2-methyl-1,2,3,4,4a,10b-hexahydro-benzo[c][1,6]naphthyridin-6-yl)-N-((R)-2-hydroxy-1-methyl-ethyl-N-isopropyl-benzamide,


a hydrate, solvate, salt, hydrate of a salt or solvate of a salt thereof, an N-oxide thereof and a salt of the N-oxide.

7. (Previously presented) A compound of formula 1 as claimed in claim 1, in which the hydrogen atoms in positions 4a and 10b are in the cis position relative to one another, or a hydrate, solvate, salt, hydrate of a salt or solvate of a salt thereof, or an N-oxide thereof or a salt of the N-oxide.

8. (Previously presented) A compound of formula 1 as claimed in claim 1 which has with respect to the chiral centers the configuration shown in formulae (1\*) or (1\*\*):







(1\*\*)

9. (Canceled)

10. (Previously presented) A pharmaceutical composition comprising one or more compounds of formula 1 as claimed in claim 1, or a pharmaceutically acceptable hydrate, solvate, salt, hydrate of a salt or solvate of a salt thereof, or an N-oxide thereof or a salt of the N-oxide, together with a pharmaceutically acceptable auxiliary and/or excipient.

11. (Canceled)

12. (Previously presented) A method for treating an illness treatable by the administration of a PDE3/4 inhibitor in a patient comprising administering to said patient in need thereof a therapeutically effective amount of a compound of formula 1 as claimed in claim 1, or a pharmaceutically acceptable hydrate, solvate, salt, hydrate of a salt or solvate of a salt thereof, or an N-oxide thereof or a salt of the N-oxide.

13. (Previously presented) A method for treating an airway disorder in a patient comprising administering to said patient a therapeutically effective amount of a compound of formula 1 as claimed in claim 1, or a pharmaceutically acceptable hydrate, solvate, salt, hydrate of a salt or solvate of a salt thereof, or an N-oxide thereof or a salt of the N-oxide.

14. (Previously presented) A method for treating dermatoses in a patient comprising administering to said patient a therapeutically effective amount of a compound of formula 1 as claimed in claim 1, or a pharmaceutically acceptable hydrate, solvate, salt, hydrate of a salt or solvate of a salt thereof, or an N-oxide thereof or a salt of the N-oxide.